Cobra Biologics Ltd., of Kelle, U.K., Pall Corp., of Port Washington, N.Y., and the Cell and Gene Therapy Catapult, of London, were jointly awarded a £1.5 million (US$1.92 million) grant from Innovate UK to investigate continuous manufacturing of adeno-associated virus for gene therapy applications. The parties have been working together on the project since September.